Herantis Pharma Oyj Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Herantis Pharma Oyj.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	15.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	30 Oct 2024

Recent future growth updates

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Mar 06

Recent updates

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Mar 06

Earnings and Revenue Growth Forecasts

HLSE:HRTIS - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	N/A	-6	-6	1
12/31/2025	N/A	N/A	0	-5	1
12/31/2024	N/A	N/A	-7	-7	1
6/30/2024	N/A	-1	-6	-6	N/A
3/31/2024	N/A	0	-5	-5	N/A
12/31/2023	N/A	0	-5	-5	N/A
9/30/2023	N/A	-3	-5	-5	N/A
6/30/2023	N/A	-5	-5	-5	N/A
3/31/2023	N/A	-7	-7	-7	N/A
12/31/2022	N/A	-9	-9	-9	N/A
9/30/2022	N/A	-10	-9	-9	N/A
6/30/2022	N/A	-10	-10	-10	N/A
3/31/2022	N/A	-12	-10	-10	N/A
12/31/2021	N/A	-13	-10	-10	N/A
9/30/2021	N/A	-13	-10	-10	N/A
6/30/2021	N/A	-13	-9	-9	N/A
3/31/2021	N/A	-11	-9	-9	N/A
12/31/2020	N/A	-9	-9	-9	N/A
9/30/2020	N/A	-9	-8	-8	N/A
6/30/2020	N/A	-9	-8	-8	N/A
3/31/2020	N/A	-9	-7	-7	N/A
12/31/2019	N/A	-8	-6	-6	N/A
9/30/2019	N/A	-7	-5	-5	N/A
6/30/2019	N/A	-6	-5	-5	N/A
3/31/2019	N/A	-5	-4	-4	N/A
12/31/2018	N/A	-4	-4	-4	N/A
9/30/2018	N/A	-3	-4	-4	N/A
6/30/2018	N/A	-2	-3	-3	N/A
3/31/2018	N/A	-2	N/A	-3	N/A
12/31/2017	N/A	-2	N/A	-3	N/A
9/30/2017	N/A	-3	N/A	-2	N/A
6/30/2017	N/A	-4	N/A	-2	N/A
3/31/2017	0	-4	N/A	-2	N/A
12/31/2016	0	-4	N/A	-3	N/A
9/30/2016	0	-5	N/A	-4	N/A
6/30/2016	0	-5	N/A	-4	N/A
3/31/2016	0	-11	N/A	-6	N/A
12/31/2015	0	-16	N/A	-7	N/A
9/30/2015	0	-18	N/A	-7	N/A
6/30/2015	0	-19	N/A	-7	N/A
3/31/2015	0	-15	N/A	-6	N/A
12/31/2014	0	-8	N/A	-4	N/A
9/30/2014	0	-6	N/A	-3	N/A
6/30/2014	N/A	-3	N/A	-2	N/A
3/31/2014	N/A	-1	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if HRTIS's forecast earnings growth is above the savings rate (1.3%).

Earnings vs Market: Insufficient data to determine if HRTIS's earnings are forecast to grow faster than the Finnish market

High Growth Earnings: Insufficient data to determine if HRTIS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if HRTIS's revenue is forecast to grow faster than the Finnish market.

High Growth Revenue: HRTIS is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if HRTIS's Return on Equity is forecast to be high in 3 years time

Herantis Pharma Oyj Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Recent updates

Herantis Pharma Plc Starts Dosing of HER-096 in the Part 1 of the Phase 1b Clinical Trial

Herantis Pharma Oyj to Report Fiscal Year 2023 Results on Mar 27, 2024

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €4.506795 million.

Herantis Pharma Plc Announces Positive Topline Data from Phase 1a Clinical Trial of HER-096

Herantis Pharma plc Announces First Healthy Volunteers Dosed in the Part 2 of the Her-096 Phase 1A Clinical Study

Herantis Pharma Plc Announces Start of Recruitment of Healthy Volunteers for Part 2 of the Ongoing Phase 1a Clinical Study of HER-096

Herantis Pharma Oyj Announces Submission of A Clinical Trial Application (CTA) for A Phase 1 Study for HER-096

Herantis Pharma Oyj to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Herantis Pharma Applies for Delisting from Nasdaq First North Growth Market Sweden

Less than half of directors are independent

Herantis Pharma Oyj to Report Second Half, 2022 Results on Mar 02, 2023

Herantis Pharma plc Announces Executive Changes

Less than half of directors are independent

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €1.4625 million.

Herantis to Focus on HER-096

High number of new and inexperienced directors

High number of new and inexperienced directors

Herantis Pharma Announces Successful rhCDNF Results With Nanoform Technology

Herantis Pharma Announces xCDNF Preclinical Candidate Selection

Earnings beat expectations

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Herantis Pharma Plc Announces Inconclusive Results from Phase II Study with Lymfactin in Breast Cancer Related Lymphedema

New 90-day low: €3.28

Herantis Pharma Oyj and Nanoform Enter into Agreement for Proof of Concept Collaboration

Herantis Pharma Oyj Announces Nomination Committee Appointments

Herantis Pharma plc Appoints Magnus Sjögren as Chief Medical Officer, Effective May 1, 2021

Herantis Pharma Oyj to Report Fiscal Year 2020 Final Results on Mar 25, 2021

New 90-day low: €3.90

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

Herantis Pharma Announces Favorable 24-Month Follow-Up Review from Phase I Lymfactin® Trial in Breast Cancer Associated Lymphedema

New 90-day low: €4.83

Ingrid Heiman to Leave Herantis Pharma's Board of Directors

Herantis Pharma Plc Appoints Tone Kvåle as Member of the Management Team

New 90-day low: €6.82

New 90-day low: €7.24

Herantis Pharma Oyj to Report Fiscal Year 2020 Results on Mar 03, 2021

New 90-day high - €8.86

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies